Stockscreener 앱 받기
2.60
3.79%
0.095
시장 영업 전:
2.66
0.06
+2.31%
Esperion Therapeutics Inc 주식(ESPR)의 최신 뉴스
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Insider Selling: Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $15,411.60 in Stock - MarketBeat
Esperion Therapeutics CFO Halladay sells $17k in stock By Investing.com - Investing.com Australia
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics CEO Koenig sells $69,546 in stock By Investing.com - Investing.com Canada
Esperion Therapeutics CFO Halladay sells $17k in stock - Investing.com
Esperion (NASDAQ: ESPR) CLO sells 5,708 shares to cover RSU tax bill - Stock Titan
Esperion Therapeutics (ESPR) CEO sells shares to pay RSU taxes - Stock Titan
Esperion (ESPR) CFO sells shares to cover taxes on vested RSUs - Stock Titan
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 7.6%Here's What Happened - MarketBeat
Esperion acquires Enbumyst maker Corstasis - MSN
Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM), Stryker (SYK) and Esperion (ESPR) - The Globe and Mail
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
ESPR (NASDAQ: ESPR) affiliate files to sell 6,424 vested shares after vesting - Stock Titan
ESPR (NASDAQ: ESPR) Form 144 files planned sale of 5,708 shares - Stock Titan
Sheldon Koenig to sell 25,578 ESPR shares (NASDAQ: ESPR) under Form 144 - Stock Titan
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - Bitget
Esperion to Present Two New Analyses From CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session - 富途牛牛
CLEAR Outcomes trial findings to be presented by Esperion Therapeutics at major cardiology event - Traders Union
Bempedoic acid data spotlight statin-intolerant, autoimmune patients - Stock Titan
Esperion to Present Two New Analyses from CLEAR Outcomes - GlobeNewswire
BofA reiterates Esperion Therapeutics stock Underperform rating By Investing.com - Investing.com Canada
Esperion Therapeutics (ESPR) CFO receives major equity grants - Stock Titan
Esperion (ESPR) CLO receives new stock and option grants - Stock Titan
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 7.8% Following Analyst Upgrade - MarketBeat
2026 cholesterol guideline backs bempedoic acid for statin-intolerant patients - Stock Titan
Operating cash flow per share of Esperion Therapeutics, Inc. – DUS:0ET - TradingView
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference - MarketBeat
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Sahm
Integral Health Asset Management LLC Purchases New Stake in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Esperion Therapeutics soars amid vague takeover speculation - MSN
Esperion Therapeutics (NASDAQ:ESPR) Price Target Raised to $5.00 - MarketBeat
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Esperion Therapeutics (ESPR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - TradingView
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm
Esperion Therapeutics Q4 2025 earnings preview - MSN
ESPR stock falls after Esperion’s mixed Q4 — retail remains unfazed, eyes ‘massive’ upcoming catalysts - MSN
H.C. Wainwright Maintains Buy on Esperion Therapeutics (ESPR) March 2026 - Meyka
Esperion Therapeutics, Inc (ESPR) Misses Q4 EPS Estimates - AlphaStreet
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 5.1%Time to Sell? - MarketBeat
Esperion Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics Reports Strong 2025 Revenue Growth, Expands Global Cardiovascular Franchise and Advances New Therapies - Minichart
Esperion Therapeutics, Inc (ESPR) Reports Q4 Earnings - AlphaStreet
Esperion Therapeutics Q4 Earnings Call Highlights - MarketBeat
Esperion Q4 2025 slides: 38% sales growth, $4.6B CHF opportunity - Investing.com Nigeria
ESPR: Record revenue growth and strategic expansion set the stage for sustained momentum in 2026 - TradingView
Esperion Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Esperion Therapeutics Q4 2025 misses EPS but sees revenue surge - Investing.com Canada
2.02%
0.77%
자본화:
|
볼륨(24시간):